Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
The disease gradually takes away the skills children have learned—leading to seizures, movement difficulties and profound ...
Detailed price information for Spruce Biosciences Inc (SPRB-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback